Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00868907 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food
A Phase 1 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT00868907 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 101 participants.
The verdict
NCT00868907, a Phase 1 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1, 2 and 3), and exit procedures.
Interventions
- DRUG 35 mg risedronate DR tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00868907
The ClinicalTrials.gov registry entry for NCT00868907 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 35 mg risedronate DR tablet is the first listed.
NCT00868907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00868907 about?
NCT00868907 is a clinical study titled "Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food". Randomized, open-label, single dose, 3-treatment, 3-period crossover study, with a 14- to 17-day washout period between doses. The study will consist of a screening visit, study center admission (preceding Treatment Periods 1, 2 and 3), 3 treatment periods (4 days each), 1 washout period (14 to 17 d...
What is the current status of trial NCT00868907?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2009-03. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00868907?
The interventions under investigation include: 35 mg risedronate DR tablet (DRUG).
Who is sponsoring clinical trial NCT00868907?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.